相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bevacizumab treatment of prostate cancer
Alexander C. Small et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Novel targets for VEGF-independent anti-angiogenic drugs
Marco Petrillo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Targeting angiogenesis for the treatment of prostate cancer
Emmanuel S. Antonarakis et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts et al.
LANCET ONCOLOGY (2012)
Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2
Tajana Tesan Tomic et al.
PROSTATE (2012)
Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
Kenji Takeuchi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2011)
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Roberto Pili et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma
Teri N. Kreisl et al.
NEURO-ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
James Kim et al.
CANCER CELL (2010)
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Farbod Shojaei et al.
CANCER RESEARCH (2010)
Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study
Daniel Keizman et al.
CLINICAL CANCER RESEARCH (2010)
The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer
John T. Isaacs
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
A. Craig Lockhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Yang-Min Ning et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
Anders Olsson et al.
MOLECULAR CANCER (2010)
Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study
Mark F. Kozloff et al.
ONCOLOGY (2010)
Cholesterol trafficking is required for mTOR activation in endothelial cells
Jing Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor Inflammation
Michael C. Schmid et al.
JOURNAL OF ONCOLOGY (2010)
Phase II study of sunitinib in men with advanced prostate cancer
M. Dror Michaelson et al.
ANNALS OF ONCOLOGY (2009)
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
O. Bratt et al.
BRITISH JOURNAL OF CANCER (2009)
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
Quincy Siu-Chung Chu
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Lenalidomide: a novel anticancer drug with multiple modalities
Christine Galustian et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
Per Bjork et al.
PLOS BIOLOGY (2009)
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model
Haiqing Li et al.
BJU INTERNATIONAL (2008)
A phase II clinical trial of sorafenib in androgen-independent prostate cancer
William L. Dahut et al.
CLINICAL CANCER RESEARCH (2008)
Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
Giuseppe Di Lorenzo et al.
EUROPEAN UROLOGY (2008)
Thalidomide: Mechanisms of action
Taraneh Paravar et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
Pingyan Cheng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Inhibition of angiogenesis by the antifungal drug itraconazole
Curtis R. Chong et al.
ACS CHEMICAL BIOLOGY (2007)
The androgen receptor negatively regulates the expression of c-Met: Implications for a novel mechanism of prostate cancer progression
Meletios Verras et al.
CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
John T. Isaacs et al.
PROSTATE (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
WL Dahut et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Antitumor effects of thalidomide analogs in human prostate cancer Xenografts implanted in immunodeficient mice
SSW Ng et al.
CLINICAL CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
High expression of the Met receptor in prostate cancer metastasis to bone
BS Knudsen et al.
UROLOGY (2002)
Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts
RJ Stewart et al.
JOURNAL OF UROLOGY (2001)
分享论文
